Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Carcinoma, Basal Cell 1

Interventions

HhAntag691 25Imiquimod 12Biopsy 12sonidegib 11Aminolevulinic Acid 9cemiplimab 8Photochemotherapy 8Nivolumab 8methyl 5-aminolevulinate 7Mohs Surgery 71-phenyl-3,3-dimethyltriazene 7Tomography, Optical Coherence 6Surgical Procedures, Operative 6Specimen Handling 5Radiotherapy 5Itraconazole 5pembrolizumab 4daromun 4Microscopy, Confocal 4Magnetic Resonance Spectroscopy 4Ipilimumab 4Curettage 4Standard of Care 3Niacinamide 3IPI-926 3CTLA-4 Antigen 33-ingenyl angelate 3tazarotene 2talimogene laherparepvec 2relatlimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Basal Cell × Chemoprevention × Dermatologic × Clear all
NCT00025051 2013-03-22

Celecoxib in Preventing Skin Cancer

National Cancer Institute (NCI)

Phase 2 Withdrawn
Dermatologic

Carcinoma, Basal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡